Blueprint Medicines (BPMC) Financial Analysis & Valuation | Quarter Chart
Blueprint Medicines (BPMC)
BPMCPrice: $129.46
Fair Value: 🔒
🔒score
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-26... more
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically def... more
Description
Shares
| Market Cap | $8.36B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kathryn Haviland |
| IPO Date | 2015-04-30 | CAGR | — |
| Employees | 682 | Website | www.blueprintmedicines.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BPMC chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.63B | P/E Ratio | -51.58 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 28.27 | P/B Ratio | 24.07 |
| P/CF Ratio | -98.2 | P/FCF Ratio | -96.54 |
| EPS | $-2.51 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 99.19% | Gross Margin | 0.97% |
| Operating Margin | -0.28% | Profit Margin | -0.17% |
| ROE | -0.15% | ROA | -0.04% |
| ROCE | -0.09% | Current Ratio | 2.8 |
| Quick Ratio | 2.75 | Cash Ratio | 0.49 |
| Debt/Equity | 0.36 | Interest Coverage | -3.13 |
| Altman Z Score | 3.68 | Piotroski Score | 4 |